<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226119</url>
  </required_header>
  <id_info>
    <org_study_id>MP-EIA-HTLV-002B</org_study_id>
    <nct_id>NCT03226119</nct_id>
  </id_info>
  <brief_title>MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study</brief_title>
  <official_title>HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MP Biomedicals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MP Biomedicals Asia Pacific Pte. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MP Biomedicals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post-market study is intended to assess the performance of the HTLV Blot 2.4 in
      repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known
      positive infection (n=50).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HTLV Blot 2.4 Post-Market Clinical Study is an open-label, multi-center, single-blind
      clinical study of neurological disorders (n=100) and HTLV known-positive (KP) specimens
      (n=50). This study is being conducted to support additional labeling claims and to further
      assess the sensitivity and specificity of the HTLV Blot 2.4 in specimens with neurological
      disorders and HTLV known positive specimens.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">May 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cohort A: 100 Neurological Disorder Specimens Cohort B: 50 HTLV Known Positive Specimens</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Clinical Sites and the Reference Core-Lab will be masked of specimen disease state</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate ≥95% agreement of HTLV Blot 2.4 results with the Reference Core Laboratory HTLV Algorithm in 100 Neurological Disorder Specimens</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To demonstrate HTLV Blot 2.4 sensitivity of ≥97.5% in 50 HTLV Known Positive Specimens</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>HTLV-I Infections</condition>
  <condition>HTLV-II Infections</condition>
  <condition>Human T-lymphotropic Virus 1</condition>
  <condition>Human T-lymphotropic Virus 2</condition>
  <condition>HTLV I Associated T Cell Leukemia Lymphoma</condition>
  <condition>HTLV I Associated Myelopathies</condition>
  <arm_group>
    <arm_group_label>HTLV Infected (n=50)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serum/plasma specimens which are HTLV I, HTLV II or HTLV I/II known positive (KP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurological Disorders (n=100)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serum/plasma specimens with symptoms or any of the following neurological disorders: Acute Disseminated Encephalitis, Amyotrophic Lateral Sclerosis, Autonomic Dysfunction, Conus Medularis Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Dermatomyositis, HAM-TSP, Meningitis, Mild Cognitive Impairment, Multiple Sclerosis, Polymyositis, Spastic Paraparesis, Sciatica</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MP Diagnostics HTLV Blot 2.4</intervention_name>
    <description>HTLV I/II Confirmation and Differentiation</description>
    <arm_group_label>HTLV Infected (n=50)</arm_group_label>
    <arm_group_label>Neurological Disorders (n=100)</arm_group_label>
    <other_name>HTLV I/II Western Blot Assay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Specimens:

          -  Male or female

          -  Biorepository specimen de-identified of PHI

          -  Specimen meets HTLV Blot 2.4 labeling collection/handling criteria

        HTLV Positive Specimens:

        Specimens with a known positive infection of HTLV I, HTLV II or HTLV I/II

        Neurological Disorders:

        Specimens with a diagnosis or symptoms consistent with any of the following neurological
        disorders:

          -  Acute Disseminated Encephalitis

          -  Amyotrophic Lateral Sclerosis (ALS)

          -  Autonomic Dysfunction

          -  Conus Medularis Syndrome

          -  Chronic Inflammatory Demyelinating Polyneuropathy

          -  Dermatomyositis

          -  HTLV associated myelopathy-tropical spastic paraparesis (HAM-TSP)

          -  Meningitis

          -  Mild Cognitive Impairment

          -  Multiple Sclerosis (MS)

          -  Polymyositis

          -  Spastic Paraparesis

          -  Sciatica

        Exclusion Criteria:

        HTLV Infected:

          -  specimens with a known infection or history of HIV, HCV or HBV

          -  specimens not meeting specimen labeling collection / handling criteria

        Neurological Disorders

          -  specimens not meeting specimen labeling collection / handling criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Dionne, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LABS, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LABS, Inc.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualtex Laboratories</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School (EVMS)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Miller L. Profile of the MP Diagnostics HTLV Blot 2.4 test: a supplemental assay for the confirmation and differentiation of antibodies to HTLV-1 and HTLV-2. Expert Rev Mol Diagn. 2016;16(2):135-45. doi: 10.1586/14737159.2016.1123622. Epub 2016 Jan 11. Review.</citation>
    <PMID>26589659</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HTLV</keyword>
  <keyword>Confirmatory</keyword>
  <keyword>Supplemental</keyword>
  <keyword>Blot</keyword>
  <keyword>HTLV-I</keyword>
  <keyword>HTLV-II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Spinal Cord Diseases</mesh_term>
    <mesh_term>Paraparesis, Tropical Spastic</mesh_term>
    <mesh_term>HTLV-I Infections</mesh_term>
    <mesh_term>HTLV-II Infections</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All clinical study data will be compiled and shared with investigators following database lock.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

